Revolution Medicines Inc (NASDAQ:RVMD) — Market Cap & Net Worth
Market Cap & Net Worth: Revolution Medicines Inc (RVMD)
Revolution Medicines Inc (NASDAQ:RVMD) has a market capitalization of $41.99 Billion ($41.99 Billion) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #654 globally and #313 in its home market, demonstrating a -5.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Revolution Medicines Inc's stock price $195.92 by its total outstanding shares 214336418 (214.34 Million). Also see Revolution Medicines Inc assets under control for a full breakdown of the balance sheet.
Revolution Medicines Inc Market Cap History: 2020 to 2026
Revolution Medicines Inc's market capitalization history from 2020 to 2026. Data shows growth from $8.49 Billion to $41.99 Billion (33.67% CAGR). Also see RVMD cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Revolution Medicines Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 1.58% | #10 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.10% | #91 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 2.24% | #8 of 263 |
Weight: Revolution Medicines Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Revolution Medicines Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Revolution Medicines Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Revolution Medicines Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
530.84x
Revolution Medicines Inc's market cap is 530.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $8.49 Billion | $42.98 Million | -$108.16 Million | 197.42x | N/A |
| 2021 | $5.39 Billion | $29.39 Million | -$187.09 Million | 183.56x | N/A |
| 2022 | $5.11 Billion | $35.38 Million | -$248.71 Million | 144.30x | N/A |
| 2023 | $6.15 Billion | $11.58 Million | -$436.37 Million | 530.84x | N/A |
Competitor Companies of RVMD by Market Capitalization
Companies near Revolution Medicines Inc in the global market cap rankings as of September 17, 2026. Review RVMD intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Revolution Medicines Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Revolution Medicines Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Revolution Medicines Inc's market cap moved from $8.49 Billion to $ 41.99 Billion, with a yearly change of 33.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $41.99 Billion | +145.98% |
| 2025 | $17.07 Billion | +82.10% |
| 2024 | $9.38 Billion | +52.51% |
| 2023 | $6.15 Billion | +20.40% |
| 2022 | $5.11 Billion | -5.36% |
| 2021 | $5.39 Billion | -36.42% |
| 2020 | $8.49 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Revolution Medicines Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $41.99 Billion USD |
| MoneyControl | $41.99 Billion USD |
| MarketWatch | $41.99 Billion USD |
| marketcap.company | $41.99 Billion USD |
| Reuters | $41.99 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS comp… Read more